Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $92.86, for a total value of $928,600.00. Following the completion of the transaction, the chief technology officer owned 1,000 shares of the company’s stock, valued at $92,860. The trade was a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Price Performance

NASDAQ:BLLN traded down $0.49 during mid-day trading on Wednesday, reaching $97.45. The stock had a trading volume of 522,419 shares, compared to its average volume of 537,016. The firm has a 50 day moving average price of $116.72 and a two-hundred day moving average price of $94.50. The stock has a market capitalization of $4.48 billion and a P/E ratio of 139.21. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The business had revenue of $109.45 million during the quarter. As a group, analysts expect that Billiontoone, Inc. will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on BLLN. Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. JPMorgan Chase & Co. lowered their price target on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. BTIG Research reduced their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Guggenheim began coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Adams Street Partners LLC bought a new stake in Billiontoone during the 4th quarter valued at $140,063,000. Baillie Gifford & Co. bought a new stake in Billiontoone in the 4th quarter worth $103,786,000. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% in the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock valued at $62,160,000 after acquiring an additional 148,446 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone in the fourth quarter valued at about $39,717,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at about $32,078,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.